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Abstract
 
Two important Ras guanine nucleotide exchange factors, Son of sevenless (Sos) and Ras guanine
nucleotide releasing protein (RasGRP), have been implicated in controlling Ras activation
when cell surface receptors are stimulated. To address the specificity or redundancy of these
exchange factors, we have generated Sos1/Sos2 double- or RasGRP3-deficient B cell lines and
determined their ability to mediate Ras activation upon B cell receptor (BCR) stimulation.
The BCR requires RasGRP3; in contrast, epidermal growth factor receptor is dependent on
Sos1 and Sos2. Furthermore, we show that BCR-induced recruitment of RasGRP3 to the
membrane and the subsequent Ras activation are significantly attenuated in phospholipase
C-
 
 
 
2–deficient B cells. This defective Ras activation is suppressed by the expression of
RasGRP3 as a membrane-attached form, suggesting that phospholipase C-
 
 
 
2 regulates
RasGRP3 localization and thereby Ras activation.
Key words: DAG • PLC-
 
 
 
2 • RasGRP3 • ERK • B cell activation
 
Introduction
 
In B and T lymphocytes, activation of the small guanosine
triphosphatase (GTPase) Ras is a crucial event that takes
place when antigen or some lymphokine receptors are
stimulated (1–7). By associating with different effector
proteins, including Raf/MEK/ERK, Ras acts as a branch
point to initiate multiple downstream signaling pathways
and, hence, influence gene expression in these cells (8).
Indeed, the Ras pathway has been implicated in supporting
survival and differentiation of pre–B cells as well as mature
B cells. Introduction of a constitutive active form of Ras
into a Rag-null background can cause progression of pro–B
cells to pre–B and subsequent mature B cells (9, 10). Con-
versely, expression of a dominant negative form of Ras
markedly reduces the number of pre–B cells and immature
B cells (11, 12). These findings, given the importance of
pre–B cell receptor (BCR) and BCR in B cell survival and
differentiation (13–17), suggest a crucial role for Ras in
pre-BCR– and BCR-mediated cell fate decision.
Ras activity cycles between a GDP-bound off and a
GTP-bound on conformation proximal to the inner surface
of the plasma membrane. Ras is inactivated by its own intrin-
sic capability to induce GTP hydrolysis to GDP, and this
GTPase activity can be accelerated by GTPase-activating
proteins (GAPs). Conversely, guanine nucleotide exchange
factors (GEFs) control the activation of Ras by catalyzing
GDP release from Ras and, thereby, facilitating its association
with GTP (18–20). Thus, Ras activity is controlled by the
balanced activities of GEFs and GAPs. Hence, two alternative,
but not necessarily mutually exclusive, models are thought
to account for Ras activation upon antigen receptor stimu-
lation as follows: (a) inhibition of GAP function; and (b) acti-
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vation of GEF activity. With regard to the first possi-
bility,  the importance of association of p62DOK with
p120RasGAP has been proposed in B cells (21, 22); this in-
teraction is thought either to allosterically inhibit GAP func-
tions, or to sequester this negative regulator, thereby physi-
cally preventing its interaction with Ras. However, the
molecular details of GAP regulation are still fragmentary.
The other side of Ras regulation, namely by GEF activity,
has been thought to be mediated by at least two types of Ras
GEFs: (a) the well-characterized Son of sevenless (Sos) fam-
ily; and (b) the recently identified Ras guanine nucleotide
releasing protein (RasGRP) family (19, 23–25). Two lines
of recent evidence favor the idea that the RasGRP family,
rather than the Sos family, could play a more dominant role
in Ras activation after antigen receptor ligation in the T cell
system. First, RasGRPs contain a diacylglycerol (DAG)-
binding C1 domain, possibly explaining the striking activa-
tion of Ras in peripheral T cells after phorbol ester stimula-
tion (26–28). Second, RasGRP1
 
 
 
/
 
 
 
 thymocytes fail to
activate Ras and phosphorylate Erk when challenged with
phorbol ester or when their TCRs are stimulated (26).
Despite striking T cell developmental defects in Ras
GRP1
 
 
 
/
 
 
 
 mice, B cell development appears to be appar-
ently normal (26). Hence, in the case of B cells, consider-
ing the existence of four isoforms of the RasGRP family,
one possibility is that another RasGRP family might play
an important role in BCR-mediated Ras activation. Alter-
natively, in contrast to T cells, BCR might dominantly uti-
lize the Sos family for Ras activation. Here, we report the
consequences of disruption of either of these GEFs and
demonstrate the mechanism by which BCR activates Ras.
 
Materials and Methods
 
Cells, Mice, Abs, and Reagents. 
 
Wild-type and various mu-
tant DT40 cells were cultured in RPMI 1640 (GIBCO™; Invi-
trogen) supplemented with 10% FCS, 1% chicken serum, 50 
 
 
 
M
2-ME (Sigma-Aldrich), 4 mM 
 
l
 
-glutamine, and antibiotics. Es-
tablishment of phospholipase C (PLC)-
 
 
 
2–deficient DT40 cells
was described previously (29). Wild-type C57BL/6J mice were
purchased from Clea Japan. Anti-Sos1 Ab, anti-Sos2 Ab, anti-
RasGRP1 Ab, and anti-RasGRP3 Ab were obtained by immu-
nizing rabbits with bacterially expressed glutathione 
 
S
 
-transferase
(GST) fusion proteins containing amino acid sequences coding
chicken Sos1 (amino acids 1241–1336), chicken Sos2 (amino ac-
ids 1200–1297), chicken RasGRP1 (amino acids 690–787), and
chicken RasGRP3 (amino acids 401–691), respectively. Anti–
chicken IgM mAb, M4 (30) was used for stimulation of BCR
and Western blotting. Anti-phospho–p44/p42 mitogen-activated
protein kinase (MAPK) polyclonal Ab, anti-phospho–p44/p42
MAPK mAb (E10), and anti-p44/p42 MAPK polyclonal Ab
were purchased from Cell Signaling Technology Inc. Anti–pan-
Ras mAb (Ab-3) was purchased from Oncogene Research Prod-
ucts. Anti–H-Ras Ab (C-20) and anti–K-Ras Ab (F234) were
purchased from Santa Cruz Biotechnology, Inc. The pEGFP-C2
vector was purchased from CLONTECH Laboratories, Inc. EGF
was purchased from TOYOBO.
 
Expression Constructs and Transfection. 
 
Chicken RasGRP3
cDNA was cloned into the pApuro expression vector. Using
QuikChange™ (Stratagene), the arginine residue (218) is sub-
stituted to glutamate to create a GEF mutant construct
(mGEFRasGRP3), and C1 domain is deleted to create a C1 do-
main deletion mutant construct (
 
 
 
C1RasGRP3). Wild-type
RasGRP3 and 
 
 
 
C1RasGRP3 were fused at its COOH terminus
to enhanced green fluorescent protein (EGFP) by the PCR
method, resulting in generation of RasGRP3–green fluorescent
protein (GFP) and 
 
 
 
C1RasGRP3-GFP. For construction of
 
 
 
C1-pbRasGRP3 and 
 
 
 
C1-
 
 
 
pbRasGRP3, the modified pAp-
uro vector was made to insert oligonucleotides encoding a polyba-
sic domain or its mutant at its 3
 
 
 
 cloning site. Thus, the resulting
polybasic domain and polybasic domain defective vector encode
the following amino acids of the COOH terminus of chicken
K-Ras: xRKHKEKMSKDGKKKKKKTKTKCIIM# or xRKH-
KEKMSKDG#, where x is the site of insertion of cDNA and # is
the stop codon. 
 
 
 
C1RasGRP3 was inserted into these vectors, re-
sulting in in-frame fusion of cDNA to the polybasic domain.
These constructs were transfected into each mutant DT40 cells by
electroporation (550 V, 25 
 
 
 
F), and selected in the presence of 0.5
 
 
 
g/ml puromycin. Human epidermal growth factor receptor
(EGFR) cDNA was transfected and selected as described previ-
ously (31). Chicken H-Ras and K-Ras cDNAs were cloned into
the pApuro expression vector and were transfected into 293T cells
by the calcium phosphate coprecipitation method. Expression of
transfected cDNAs was confirmed by Western blot analysis.
 
Generation of Various Deficient DT40 Cells. 
 
Based on pub-
lished sequence of murine Sos1, Sos2, RasGRP1, and human
RasGRP3, we searched each chicken homologue using the ex-
pressed sequence tag (EST) database and obtained each chicken
cDNA by RT-PCR with RNA from DT40 B cells. Genomic
clones of Sos1, Sos2, RasGRP1, and RasGRP3 were obtained by
PCR using oligonucleotides designed from each cDNA sequence
and genomic DNA as a template. The targeting vector, pSos1-
bleo, pSos1-hygro, or pSos1-puro was constructed by replacing
the genomic fragment containing exons that correspond to mu-
rine Sos1 GEF domain, amino acid residues 740–947, with bleo,
hygro, or puro cassette. The targeting constructs for Sos2 were
designed for neo and hisD cassettes to replace the genomic frag-
ment corresponding to chicken Sos2 GEF domain, amino acid
residues 814–908. The hisD and zeo targeting constructs for
RasGRP1 were made by replacing the genomic fragment con-
taining chicken RasGRP1 GEF domain, amino acid residues
169–316, with hisD and zeo cassettes. The targeting constructs
for RasGRP3 were designed for neo and bsr cassettes to replace
the genomic fragment containing exons corresponding to
chicken RasGRP3 GEF domain, amino acid residues 124–361.
These targeting vectors were sequentially transfected into various
mutant DT40 cells, resulting in generation of Sos1-, Sos2-,
RasGRP1-, RasGRP3-, Sos1/Sos2 double-, and RasGRP1/
RasGRP3 double-deficient DT40 cells. Selection for each drug-
resistant clone was performed by using 0.3 mg/ml phleomycin, 2
mg/ml hygromycin, 0.5 
 
 
 
g/ml puromycin, 1 mg/ml histidiol, 50
 
 
 
g/ml blastcidin, and 2 mg/ml G418.
 
Northern Blot Analysis. 
 
RNA was prepared from wild-type
DT40 cells using the guanidium thiocyanate method. Total RNA
(20 
 
 
 
g) was separated in 1.2% formaldehyde gel, transferred to
Hybond-N
 
 
 
 membrane (Amersham Biosciences), and probed
with 
 
32
 
P-labeled chicken cDNA. 
 
 
 
-actin (32) was used for inter-
nal control.
 
Immunoprecipitation and Western Blot Analysis. 
 
For immuno-
precipitation, cells were solubilized in NP-40 lysis buffer supple-
mented with protease and phosphatase inhibitors as described
previously (33), and precleared lysates were incubated with
proper Abs and protein A–agarose. For Western blot analysis, im- 
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munoprecipitates or cleared-cell lysates were resolved on SDS-
PAGE, transferred to polyvinyldifluoride membrane (Bio-Rad
Laboratories), and detected by the indicated Abs using the en-
hanced chemoluminescence system (Amersham Biosciences).
 
Ras-GTP Assay. 
 
Ras-GTP assay was performed as de-
scribed previously (34, 35). In brief, bacterially expressed GST–
Ras binding domain (amino acids 1–149 of human cRaf-1 fused
to GST) prebounded glutathione-Sepharose beads was prepared.
Each M4-stimulated cell lysate in Mg
 
2
 
 
 
-containing lysis buffer
was incubated with the beads for 30 min at 4
 
 
 
C. Bound proteins
were eluted with SDS-PAGE sample buffer and resolved on
15% SDS-PAGE and subjected to Western blotting with anti–
pan-Ras Ab.
 
Calcium Measurements. 
 
Calcium mobilization was measured
as described previously (34). In brief, cells were loaded in Fura-2
AM at 37
 
 
 
C for 45 min, and washed twice, adjusted to 10
 
6
 
 cells/
ml. Cells were stimulated with 1.5 
 
 
 
g/ml M4 mAb at 37
 
 
 
C.
Continuous monitoring of fluorescence from cell suspension was
performed using a fluorescence spectrophotometer (model F-2000;
Hitachi).
 
IP
 
3
 
 Generation Assay. 
 
2 
 
 
 
 10
 
6
 
 cells were stimulated with 1.5
 
 
 
g/ml M4 mAb at 37
 
 
 
C for indicated times. Production of inos-
itol 1,4,5-triphosphate (IP
 
3
 
) was measured using a commercial IP
 
3
 
assay system (Biotrak TRK 1000; Amersham Biosciences) follow-
ing the manufacturer’s protocol.
 
Lentiviral Transduction. 
 
The cDNA encoding GEF mutant
of murine RasGRP3 (amino acid 218; arginine to glutamate)
was cloned into modified pLenti6/V5-DEST (Invitrogen) con-
taining EGFP as an expression marker downstream of the inter-
nal ribosomal entry site. The empty vector was used as a nega-
tive control. Culture supernatants containing lentivirus were
generated using 293FT cell line and ViraPower Lentiviral Sup-
port Kit (Invitrogen) according to the manufacturer’s instruc-
tion. Collected supernatants were centrifuged at 60,000 
 
g
 
 for
2 h, and the virus pellets were resuspended in culture medium at
100:1 volume. Preparation of murine splenic B cells was de-
scribed previously (36), and isolated B cells were transduced
with lentivirus as follows. Purified resting B cells (10
 
6
 
) were sus-
pended in 500 
 
 
 
l of growth medium consisted of RPMI 1640
supplemented with 10% FCS, 50 
 
 
 
M 2-ME, 2 mM 
 
l
 
-gluta-
mine, and 4 mM sodium pyruvate, and followed by the addition
of 100 
 
 
 
l of lentiviral supernatants. Hexadimethrine bromide
(Sigma-Aldrich) was added at the final concentration of 8 
 
 
 
g/
ml. The culture plates were centrifuged at 30
 
 
 
C with 2,500 rev-
olutions/min for 90 min. 3 d after transfection, cells were col-
lected and subjected to Western blot analysis using phospho-
p44/p42 MAPK mAb (E10) or RT-PCR.
 
RT-PCR. 
 
Expression levels of murine RasGRP3 and its
GEF mutant (mGEFRasGRP3) were analyzed by semi-quantita-
tive RT-PCR. In brief, total RNA was extracted from 4 
 
 
 
 10
 
5
 
cells using TRIzol (Invitrogen). Obtained RNA was reverse tran-
scribed using random hexamer primer (TAKARA BIO) with
SuperScriptII (Invitrogen) according to the manufacturer’s
instruction. For amplification of wild-type RasGRP3, 5
 
 
 
-CAA-
ACCAAGTGCGCAACAAAG-3
 
 
 
 and 5
 
 
 
-CTCCTCCATCC-
AGTCTGGGAA-3
 
 
 
 were used as forward and reverse primers,
and cycled 45 times at 94
 
 
 
C for 30 s, 63.5
 
 
 
C for 30 s, and 72
 
 
 
C
for 30 s. For amplification of mGEFRasGRP3, 5
 
 
 
-CAAAC-
CAAGTGCGCAACAAGA-3
 
 
 
 was used as a forward primer,
and the reverse primer was the same with wild type, and cycled
45 times at 94
 
 
 
C for 30 s, 65.5
 
 
 
C for 30 s, and 72
 
 
 
C for 30 s.
GAPDH was amplified as an internal control using 5
 
 
 
-CCAT-
CACCATCTTCCAGGAG-3
 
 
 
 and 5
 
 
 
-CCTGCTTCACCAC-
CTTCTTG-3
 
 
 
 as forward and reverse primers. Each PCR was
performed using AmpliTaq Gold™ (Applied Biosystems).
 
Subcellular Analysis of RasGRP3. 
 
Subcellular fractionation
was performed as described previously (34) with several modifica-
tions. In brief, cells were incubated on ice water for 10 min and
further incubated in the presence or absence of 10 
 
 
 
g/ml M4 for
30 min. Cells were stimulated at 37
 
 
 
C for 10 min and resuspended
in hypotonic lysis buffer. Proteins were separated by 7% SDS-
PAGE and analyzed by Western blotting using anti-RasGRP3 Ab.
 
Visualization of Membrane Translocation of RasGRP3-GFP.
 
Wild-type DT40 cells expressing RasGRP3-GFP or its C1 do-
main deletion mutant (
 
 
 
C1RasGRP3-GFP) were incubated with
5 
 
 
 
g/ml anti–chicken IgM mAb (M4) on ice for 20 min. PLC-
 
 
 
2–deficient DT40 cells expressing RasGRP3-GFP were also in-
cubated with M4 under the same condition. The cells were
washed with ice-cold PBS and incubated at 37
 
 
 
C for 0 and 10
min followed by fixation with 0.4% paraformaldehyde (Sigma-
Aldrich). Membrane translocation of RasGRP3-GFP fusion pro-
tein was visualized by a laser scanning confocal microscope
(model LSM 510; Carl Zeiss MicroImaging, Inc.).
 
Flow Cytometric Analysis. 
 
Cell surface expression of BCR or
EGFR on various mutant DT40 cells was analyzed by FACSCal-
ibur™ (Becton Dickinson) using FITC-conjugated anti–chicken
IgM Ab (Bethyl) or mouse anti–human EGFR mAb and FITC-
labeled anti–mouse IgG (Cappel). Expression level of EGFP was
also monitored by FACSCalibur™.
 
Results
 
Requirement for PLC-
 
 
 
2 in BCR-mediated Ras Activation.
 
Given the previous evidence that BCR-mediated Erk acti-
vation is impaired in PLC-
 
 
 
2–deficient DT40 B cells (37),
we first examined whether Ras activation is also perturbed
in the mutant cells. As shown in Fig. 1 A, when compared
with wild-type DT40 cells, BCR-mediated Ras activation
was decreased by 
 
 
 
50% in PLC-
 
 
 
2–deficient cells. The
anti-pan Ras Ab recognized two species of Ras in chicken
DT40 B cells, presumably representing K-Ras (Fig. 1 B, top
band) and H-Ras (Fig. 1 B, bottom band). Indeed, expres-
sion of the chicken K-Ras or H-Ras cDNA in 293T cells
gave rise to a protein that comigrated with K-Ras or H-Ras
in DT40 B cells, respectively (Fig. 1 B). Thus, PLC-
 
 
 
2 is re-
quired for activation of both isoforms of Ras, which, in turn,
contributes to Erk activation in BCR signaling context.
When temporal kinetics between Ras and Erk activation
in wild-type DT40 cells were compared, the Erk activation
was still sustained after 10 min of BCR stimulation despite
a significant decline of Ras activation (Fig. 1 A). Therefore,
in addition to regulation by Ras, another Ras-independent
pathway is likely to operate on sustaining ERK activation.
This Ras-independent pathway appears to lie downstream
of PLC-
 
 
 
2, because the sustained Erk activation at 10 min
was abolished in PLC-
 
 
 
2–deficient DT40 B cells.
Once PLC-
 
 
 
2 is activated upon BCR engagement, the
activated PLC-
 
 
 
2 converts phosphatidylinositol 4,5-bis-
phosphate into the two second messengers, DAG and inos-
itol 1,4,5-trisphosphate (IP
 
3
 
), which result in protein kinase
C activation and calcium increases, respectively (38–41).
To examine the relative importance of DAG and IP
 
3
 
 in
BCR-mediated Ras activation, complementation experi- 
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ments were performed with either PMA or ionomycin. In
contrast to PMA treatment, addition of ionomycin to BCR
cross-linking on PLC-
 
 
 
2–deficient DT40 B cells barely
stimulated Ras activation (Fig. 1 C), suggesting that DAG
plays a more important role in Ras activation.
 
Targeted Disruption of Sos and RasGRP Family. 
 
Next,
we focused on the connection between PLC-
 
 
 
2 and Ras
activation. Because RasGRP family, but not Sos family, has
a DAG-binding C1 domain, we reasoned that RasGRP
family, rather than Sos family, might function as a down-
stream molecule of PLC-
 
 
 
2, thereby contributing to BCR-
mediated Ras activation. To directly address the necessity or
redundancy of these molecules in BCR-mediated Ras acti-
vation, a genetic strategy was taken using DT40 B cells.
Two members of Sos (Sos1 and Sos2) and four members of
Figure 1. Requirement for PLC- 2 in BCR-mediated Ras activation.
(A) BCR-mediated Ras and ERK activation in wild-type, PLC- 2–deficient
DT40 B cells. For Ras activation, 107 cells/lane were stimulated with
5  g/ml M4, and cell lysates were mixed with beads containing the Ras
binding domain of Raf. Elutes of the beads (top) or cell lysates (bottom)
were subjected to Western blot analysis with anti–pan-Ras mAb. AP,
affinity precipitation. For ERK activation, 107 cells were stimulated with
5  g/ml M4, and cell lysates (2   106 cells/lane) were analyzed by
Western blotting with anti-phospho–p44/p42 MAPK polyclonal Ab
(top) and anti-p44/p42 MAPK polyclonal Ab (bottom). (B) Protein ex-
pression analysis of chicken H-Ras and K-Ras. Total cell lysates of DT40
cells (107 cells/lane) and 293T cells transfected with chicken H-Ras or
K-Ras cDNA were prepared and analyzed by Western blotting using
anti–pan-Ras, anti–H-Ras, and anti–K-Ras Abs. Although the bottom
band was the major product of transfected chicken H-Ras in 293T cells,
the faint top band, which has the same electrophoretic mobility as K-Ras,
was detected when overexposed. Thus, the minor portion of the top
band observed in DT40 B cells is likely to be composed of H-Ras. (C)
Complementation of Ras activation after costimulation of BCR with
PMA or ionomycin. PLC- 2–deficient DT40 B cells were stimulated and
analyzed as in A with 50 ng/ml PMA or 100 nM ionomycin. This con-
centration of ionomycin can induce calcium mobilization to the same
extent as induced by M4 stimulation on wild-type DT40 B cells.
Figure 2. Generation of Sos1/Sos2 double-, RasGRP1/RasGRP3
double-, and RasGRP3-deficient DT40 B cells. (A) RNA expression of
Sos1,  Sos2,  RasGRP1, and RasGRP3 was analyzed by Northern blot
analysis using each chicken cDNA probe (top) or  -actin (bottom). The
specific radio activity of each probe was roughly the same. Positions of
28S rRNA are shown. (B) Sos1, Sos2, RasGRP1, and RasGRP3 protein
expression in wild-type and various mutant DT40 cells. Each protein was
immunoprecipitated and detected by Western blotting with each specific
Abs. Sos1 Sos2 , Sos1/Sos2 double-deficient DT40 cells. GRP3 ,
RasGRP3-deficient DT40 cells. GRP1 GRP3 , RasGRP1/RasGRP3
double-deficient DT40 cells. (C) Cell surface expression of BCR on
wild-type and various DT40 mutants (see Fig. 6 A for designation). (D) Cell
surface expression of transfected EGFR on wild-type and mutant DT40 cells.Oh-hora et al. 1845
RasGRP (RasGRP1–RasGRP4; references 42–47) are
known to be expressed with their combinations in a given
cell type. RNA blot analysis of DT40 cells revealed that
Sos1, Sos2, RasGRP1, and RasGRP3 were expressed in this
cell line (Fig. 2 A). Hence, we established B cell lines lacking
each gene encoding these proteins, either individually or in
combination. Among these lines, in this analysis we particu-
larly concentrated on analysis of DT40 B cell lines delet-
ing  Sos1/Sos2 doubly, RasGRP1/RasGRP3 doubly, and
RasGRP3 alone. The lack of these proteins was verified by
Western blot analysis (Fig. 2 B). The level of cell surface ex-
pression of BCR on these deficient lines was essentially the
same as that on parental DT40 cells (Fig. 2 C). In addition to
BCR, transfected EGFR was used as another prototype of
receptors with potentially different signaling requirements.
RasGRP3 Is Necessary for BCR-mediated Ras Activation,
Whereas Sos Family Is Necessary for EGFR-mediated Ras Acti-
vation.  As shown in Fig. 3 A, BCR-mediated Ras acti-
vation was unaffected in Sos1/Sos2 double-deficient
DT40 cells, but was decreased by  60% in RasGRP3-
deficient cells. This defective Ras activation was exacer-
bated to a small degree by double knockouts of RasGRP3
and RasGRP1, although RasGRP1 single-deficient DT40
cells exhibited apparently normal BCR-mediated Ras
activation (unpublished data). Hence, we conclude that
BCR-mediated Ras activation requires RasGRP3, but
not the Sos family, in DT40 B cells. In addition,
RasGRP1 appears to function as a redundant molecule of
RasGRP3 and the relative importance of RasGRP3 in
DT40 B cells is presumably attributable to dominant ex-
pression of RasGRP3 rather than RasGRP1 particularly
in this cell line (Fig. 2 A). Consistent with the defective
Ras activation in RasGRP3- or RasGRP1/RasGRP3
double-deficient DT40 cells, Erk activation was decreased
in these mutants. However, the kinetics of Erk activation
in these mutants was distinct from that of Ras, being
marked at 1 min. These data imply that a Ras-indepen-
dent pathway may compensate for the defective Erk acti-
vation in an attempt to cope with the deficit, particularly
at the later time point.
In contrast to BCR, EGFR-mediated activation of both
Ras and Erk was substantially reduced in Sos1/Sos2 dou-
ble-deficient DT40 B cells and slightly perturbed in
RasGRP3- or RasGRP1/RasGRP3 double-deficient cells
(Fig. 3 B). This decrease cannot be ascribed to decreased
expression of EGFR on DT40 B cells, because the level of
cell surface expression of EGFR was similar among these
clones (Fig. 2 D). Collectively, these data reveal that two
Figure 3. Differential requirement for RasGRP and Sos family in
BCR- or EGFR-mediated Ras activation. (A) BCR-mediated Ras and
ERK activation in wild-type, Sos1/Sos2 double-, RasGRP3-, and
RasGRP1/RasGRP3 double-deficient DT40 cells. Ras and ERK activation
was measured as described in Fig. 1. (B) EGFR-mediated Ras and ERK
activation in each deficient DT40 cell. Cells were stimulated by 50 ng/ml
EGF and analyzed as in Fig. 1. These experiments were performed at least
three times and the representative results are shown.
Figure 4. Requirement for RasGRP3 in BCR-mediated ERK activation
in primary B cells. (A) Expression of mGEFRasGRP3 in infected B cells.
Splenic B cells from C57BL/6J mice were transduced with a GEF mutant
of mouse RasGRP3 (mGEFRasGRP3) by lentivirus. Transduction effi-
ciencies were monitored by EGFP expression. Fluorescence intensities of
untransduced cells are shown in dashed lines (top). Expression levels of
endogenous RasGRP3 and infected mGEFRasGRP3 were analyzed by
RT-PCR as described in the Materials and Methods (bottom). (B) Atten-
uation of Erk activation by the expression of mGEFRasGRP3. Infected
cells were stimulated with 12  g/ml anti–mouse IgM and ERK activation
was measured using anti-phospho–p44/p42 MAPK mAb (E10) (top) and
anti-p44/p42 MAPK Ab (bottom).A Role of RasGRP3 in B Cell Receptor Signaling 1846
types of receptors utilize distinct types of Ras GEFs to acti-
vate Ras in a given cell type.
To determine the importance of RasGRP family, partic-
ularly RasGRP3, in primary B cells as well, we took an
approach of introducing a dominant-negative form of
RasGRP3 into primary B cells by using a lentivirus system.
Based on the data that overexpression of the GEF mutant
of RasGRP3 in wild-type DT40 B cells inhibited BCR-
mediated Ras activation (unpublished data), the similar
mutant using the mouse RasGRP3 cDNA was subcloned
into the HIV-based lentiviral vector containing a bicis-
tronic mRNA encoding GFP. Because the Erk assay,
rather than the Ras assay, needs a relatively small amount of
infected B cells, we monitored BCR-mediated Erk activity
in infected primary B cells. As shown in Fig. 4 B, primary
B cells infected with a dominant negative form of
RasGRP3 manifested a decrease in BCR-mediated Erk ac-
tivation, compared with control viruses.
To formally demonstrate that PLC- 2 acts upstream to
RasGRP3 in the context of BCR signaling, we examined
the effect of disruption of RasGRP3 on PLC- 2 activa-
tion. As demonstrated in Fig. 5, BCR-mediated IP3 gener-
ation and subsequent calcium mobilization were unaffected
in RasGRP3-deficient DT40 cells, supporting the idea that
PLC- 2 lies upstream of RasGRP3 in BCR signaling.
The Catalytic Activity and C1 Domain of RasGRP3 Are
Required for BCR-mediated Ras Activation.  The preceding
results suggest that RasGRP3, when associated with the
membrane by its interaction with DAG, gains access to its
substrate Ras, converting it to the GTP-bound active form.
This hypothesis predicts requirement for both catalytic ac-
tivity and C1 domain of RasGRP3 in BCR-mediated Ras
activation. These data are presented in Fig. 6. Introduction
of wild-type RasGRP3, but neither its GEF nor C1 dele-
tion mutant, into RasGRP3-deficient DT40 B cells re-
stored BCR-mediated Ras activation.
Expression of RasGRP3 as a Membrane-attached Form in
PLC- 2–deficient Cells Restores Ras Activation. By subcel-
lular fractionation in wild-type DT40 B cells, RasGRP3 was
localized in the membrane fraction before BCR stimulation
to some extent. When stimulated, the stoichiometry of
membrane-associated RasGRP3 was reproducibly, albeit to
a small degree, enhanced. To demonstrate the importance of
the interaction between DAG and the C1 domain of
RasGRP3 in its translocation to the membrane, we exam-
ined the RasGRP3 status in PLC- 2–deficient DT40 B
cells. As expected, this BCR-mediated increase could not be
Figure 5. BCR-mediated PLC- 2 activation is not affected by loss of
RasGRP3. Cells were stimulated by 1.5  g/ml M4 for indicated time
periods and subjected to the following analyses. (A) Calcium mobilization.
Intracellular-free calcium levels in Fura-2–loaded cells were monitored by
a fluorescence spectrophotometer. (B) IP3 generation. Soluble IP3 was
extracted from 2   106 cells, and IP3 generation was measured by a
Biotrak competitive binding assay system. The results were shown by
mean   standard error of three independent experiments.
Figure 6. Both catalytic activity and C1 domain of RasGRP3 are
required in BCR-mediated Ras activation. (A) Schematic diagram of
various mutant RasGRP3 constructs. (B) Protein expression analyses of
various mutant DT40 cell lines. Wild-type, RasGRP3-, or PLC- 2–
deficient DT40 B cells expressing various RasGRP3 mutants are shown.
Endogenous RasGRP3 is also shown in wild-type or PLC- 2–deficient
DT40 cells. Whole cell lysates prepared from 2   106 cells were analyzed
by Western blotting using anti-RasGRP3 Ab or anti-BLNK Ab. (C)
Analysis of BCR-mediated Ras activation in RasGRP3-deficient cells ex-
pressing wild-type RasGRP3 and its mutants was performed as described
in Fig. 1. Each experiment was repeated at least three times.Oh-hora et al. 1847
observed in the mutant cells. Furthermore, the C1 deletion
mutant of RasGRP3 ( C1RasGRP3) failed to move to the
membrane fraction after BCR engagement (Fig. 7 A).
To further substantiate our conclusion, we performed
microscopic analysis using RasGRP3 harboring GFP. As
demonstrated in Fig. 7 B, wild-type RasGRP3-GFP, but
not  C1RasGRP3-GFP, began to move to the membrane
after 1 min of stimulation of BCR, and this membrane as-
sociation persisted until at least 10 min after stimulation.
After 10 min of stimulation, some DT40 cells exhibited
RasGRP3-GFP at perinuclear region in addition to the
membrane. In contrast to wild-type DT40 cells, in a PLC-
 2–deficient background, wild-type RasGRP3-GFP could
not move to the membrane.
To address whether the defect in translocation of
RasGRP3 in PLC- 2–deficient DT40 B cells causes insuffi-
cient Ras activation, a chimera including  C1RasGRP3
and a polybasic domain of K-Ras ( C1-pbRasGRP3) and
its defective mutant ( C1- pbRasGRP3; reference 48)
were expressed in PLC- 2–deficient DT40 B cells (Fig. 6
A). As expected, before BCR stimulation,  C1-pbRas
GRP3 was partitioned more into the membrane than wild-
type RasGRP3 (Fig. 7 C). Ras activation status at resting
level was increased by expression of  C1-pbRasGRP3 in
PLC- 2–deficient cells. When ligated by BCR, these cells
exhibited a significant increase in Ras activation to the ex-
tent observed in wild-type DT40 B cells. These data suggest
that membrane targeting of RasGRP3 can overcome the
need for association of its C1 domain with DAG. However,
a decline in active Ras after 10 min of BCR stimulation in
wild-type DT40 cells (Fig. 1 A) was not recapitulated by
expression of  C1-pbRasGRP3 (Fig. 7 C).
It has been shown that H-Ras and K-Ras are differen-
tially localized in membrane rafts and outside the rafts, re-
spectively, by the difference of their COOH-terminal
membrane targeting sequence (49). Both H- and K-Ras are
prenylated, but H-Ras is additionally modified by palmi-
toylation, whereas K-Ras contains a polybasic sequence
(50, 51). Hence, activation of both H-Ras and K-Ras by
the chimera containing the polybasic domain of K-Ras
( C1-pbRasGRP3) was somewhat unexpected. But, con-
sidering redistribution of H-Ras from the rafts into the
bulk plasma membrane during receptor activation (49, 52,
53), this movement could provide H-Ras the possibility to
gain access to  C1-pbRasGRP3. Alternatively, a small
amount of  C1-pbRasGRP3 might be located in rafts un-
der our experimental conditions, which, in turn, is respon-
sible for H-Ras activation.
Discussion
Our previous work has pointed to a role for PLC- 2 in
Erk activation in response to BCR stimulation (37). The
data presented here demonstrate that RasGRP3 couples
PLC- 2 to Ras, accounting at least partly for the defective
BCR-mediated Erk activation in PLC- 2–deficient B
cells. In addition, our results show that BCR and EGFR
Figure 7. Membrane localization of RasGRP3 is necessary for Ras
activation after BCR ligation. (A) Subcellular analysis of RasGRP3.
Wild-type, PLC- 2–deficient, wt/RasGRP3 , and  C1/RasGRP3 
DT40 cells were stimulated by M4 for 10 min ( ) and left unstimulated
( ). Membrane fractions were resolved by SDS-PAGE and immunoblotted
with anti-RasGRP3 Ab or anti-IgM Ab. (B) Impaired membrane translo-
cation of RasGRP3 in PLC- 2–deficient DT40 cells. Wild-type DT40
cells expressing RasGRP3-GFP (top) or its C1 deletion mutant (middle,
 C1RasGRP3-GFP) were stimulated with anti–chicken IgM (M4) for
indicated periods. PLC- 2–deficient DT40 cells expressing RasGRP3-
GFP were stimulated with M4 under the same condition (bottom). After
the stimulation, cells were fixed and subcellular localization of RasGRP3-
GFP fusion protein was visualized by confocal microscope as described in
Materials and Methods. Among 100 cells counted for membrane localization,
the numbers that showed clear membrane localization were 68   16 for
wild-type DT40 expressing RasGRP3-GFP, 8   1 for wild-type DT40
cells expressing  C1RasGRP3-GFP, and 7   1 for PLC- 2–deficient
DT40 cells expressing RasGRP3-GFP from three independent experiments.
The representative results are shown. (C) Restoration of Ras activation
by expression of a membrane-attached form of RasGRP3 in PLC- 2–
deficient DT40 cells. PLC- 2–deficient DT40 cells expressing chimeras
are shown as in Fig. 6 A.  C1RasGRP3 harboring the polybasic carboxyl
terminus of K-Ras ( C1-pbRasGRP3/PLC- 2 ) or its polybasic amino
acid–defective mutant ( C1- pbRasGRP3/PLC- 2 ) were stimulated
and analyzed with Ras activation as in Fig. 1 (top, GTP-bound Ras;
middle, total Ras). Subcellular analyses of transfected RasGRP3 and
endogenous RasGRP3 were also carried out before BCR stimulation.
Samples were immunoblotted with anti-RasGRP3. Anti-IgM that recog-
nized a   heavy chain was used as a control for membrane fraction, and
anti-ERK was used as a control for cytosolic fraction (bottom). C, cyto-
solic fraction. M, membrane fraction.A Role of RasGRP3 in B Cell Receptor Signaling 1848
utilize distinct types of RasGEFs, the RasGRP family and
the Sos family, respectively, to activate Ras in the same
cellular context.
Because the two src homology (SH) 3 domains of Grb2
bind to proline-rich residues near the C terminus of Sos,
Grb2 is thought to mediate the translocation of Sos to the
plasma membrane, thereby allowing Sos to activate mem-
brane-bound Ras (54–58). In the case of EGFR, a require-
ment for Sos1 in EGFR-mediated Erk activation has been
demonstrated already by using Sos1 /  fibroblasts, but this
Erk activation is only partially blocked in this mutant cell
(59, 60), therefore, subsequently raising the question of
whether the remaining Erk activation is accounted for by
residual Sos2 or by other GEF families. Hence, an almost
complete block of EGER-mediated Ras and subsequent
Erk activation in Sos1/Sos2 double-deficient DT40 B cells
(Fig. 3 B) supports the former possibility. Furthermore, this
result, together with our previous evidence that Grb2 is re-
quired for EGFR-mediated Ras activation in DT40 B cells
(31), provides genetic evidence that the aforementioned
mechanism indeed operates in B cells as well, at least in the
case of transmembrane receptor tyrosine kinase signaling.
As in T cells, treatment of DAG analogues such as phor-
bol esters (PMAs) can induce the drastic activation of Ras in
B cells (3), suggesting the existence of other Ras activation
modes, in addition to the Grb2–Sos mechanism. This
PMA-dependent Ras activation was initially thought to be
mediated by protein kinase C isoforms containing single or
double C1 domains. However, recent identification of Ras-
GRPs as Ras activators possessing the C1 domain has in-
spired the possibility that RasGRPs are additional potential
candidates to connect between PMA and Ras (23). Indeed,
like a complete block of PMA-induced Ras activation in
RasGRP1 /  thymocytes (26), RasGRP1/RasGRP3 dou-
ble-deficient DT40 cells manifested almost complete block
of PMA-induced Ras activation (unpublished data).
In fact, RasGRPs function in the BCR signaling con-
text, because our data demonstrate the inhibition of BCR-
mediated Ras activation in RasGRP1/RasGRP3 double-
deficient DT40 B cells (Fig. 3 A). Despite a significant
decrease in BCR-mediated Ras activation, this mutant cell
line still exhibits Ras activation, which could be explained
by the following possibilities. First, as there exists three Ras
GEF families (RasGRF, RasGRP, and Sos family; refer-
ence 23), the full BCR-mediated Ras activation might re-
quire other GEF families, Sos and/or RasGRF, in addition
to RasGRP. Based on our data using Sos1/Sos2 double-
deficient DT40 B cells, dominant involvement of the Sos
family would be unlikely. Nevertheless, considering that a
gene knockout approach sometimes causes functional up-
regulation of other molecules in an attempt to cope with
the deficit, it is still possible that the Sos family plays a role,
albeit small, in BCR-mediated Ras activation. This possi-
bility might explain the fact that Ras activation takes place,
at least partly, independent of PLC- 2 (Fig. 1 A), as Sos ac-
tivation does not require PLC- . Second, because ablation
of both RasGRP1 and RasGRP3 results in a slightly more
severe defect in Ras activation than in single RasGRP3 de-
letion (Fig. 3 A), another RasGRP member (RasGRP2 or
RasGRP4) could be a candidate for mediating the residual
BCR-mediated Ras activation. Third, assuming that BCR
activates Ras through operating two mechanisms concomi-
tantly, by activating Ras GEFs and by inhibiting Ras GAPs,
the residual Ras activation in RasGRP1/RasGRP3 dou-
ble-deficient cells could be due to ongoing inhibition of
Ras GAPs during the BCR signal (8). Additional studies
are underway to define which of the preceding possibilities
is the most likely in DT40 B cells.
Because both Grb2–Sos and PLC- 2–RasGRP path-
ways coexist in B cells, a question arises about how their
selective engagement, depending on receptor types such as
BCR or EGFR, takes place for Ras activation. Both recep-
tors use Grb2 and PLC- 2 in their signal transduction, be-
cause BCR-mediated Rac1 activation or EGFR-mediated
calcium response is inhibited in Grb2- or PLC- 2–defi-
cient DT40 B cells, respectively (reference 61; unpublished
data). Thus, why would Grb2 or PLC- 2 be used more
preferentially for EGFR- or BCR-mediated Ras activa-
tion, respectively? As the NH2-terminal Grb2 SH3 domain
is able to bind to proline-rich residues in the B cell linker
(BLNK) as well as Sos (62), this Grb2-dependent associa-
tion may be skewing more toward the BLNK when BCRs
are stimulated. Indeed, this type of induced interaction be-
tween a proline-rich sequence in CD3  and an SH3 do-
main of adaptor molecule Nck has been reported in TCR-
stimulated T cells (63). Similarly, the association between
Grb2 and the BLNK might be induced or stabilized upon
BCR engagement, possibly sequestering Sos from Grb2.
Hence, the selection of binding partners for Grb2, depend-
ing on receptor types, may underlie the basis for differential
outcomes through Grb2.
In contrast to BCR, EGFR did not essentially require
PLC- 2 for Ras activation in DT40 B cells (unpublished
data). This result is consistent with previous evidence that
EGFR-mediated Erk activation occurs normally in PLC-
 1 /  fibroblasts (64). These observations might simply
suggest that DAG, a product of PLC- 2 action, is neces-
sary, but not sufficient, for activation of RasGRP3. If so,
BCR, but not EGFR, could provide the second signal, in
addition to generating DAG, both of which are required
for activation of RasGRP3. Alternatively, given the rela-
tively small activation of PLC- 2 upon EGFR engage-
ment, compared with the BCR (unpublished data), the dif-
ferential requirement for PLC- 2 might reflect the
quantitative differences; low levels of PLC- 2 activity are
not sufficient for activation of RasGRP3.
Two lines of our evidence shown here support the pro-
posed model that PLC- , after being activated upon anti-
gen receptor engagement, generates DAG in the plasma
membrane, thereby facilitating membrane recruitment of
RasGRPs and its subsequent interaction with Ras (27).
First, the membrane recruitment of RasGRP3 was severely
affected by loss of PLC- 2, whereas absence of RasGRP3
did not affect PLC- 2 activation. Moreover, this RasOh-hora et al. 1849
GRP3 recruitment required its C1 domain. Second, the
necessity of membrane localization of RasGRP3 for its ac-
tivation was demonstrated by experiments using its mem-
brane-attached construct (Fig. 7 C,  C1-pbRasGRP3). In
line with this model, the defective membrane recruitment
of RasGRP1 in Vav3-deficient DT40 cells is likely ac-
counted for by the insufficient PLC- 2 activation in this
mutant line (65). Recent results indicate that RasGRP1
may be involved not only in the stimulation of Ras at the
plasma membrane but also at the Golgi apparatus in COS
cells and Jurkat cells (66). Indeed, consistent with a previ-
ous report (67), in addition to the plasma membrane local-
ization of RasGRP3 in DT40 cells, we also observed that
RasGRP3 could localize at the perinuclear region, presum-
ably Golgi in some DT40 cells after 10 min of BCR stimu-
lation (Kashiwagi, K., and N. Saito, personal communica-
tion). Hence, it is possible that translocation of RasGRP3
to the perinuclear region might participate in the sustained
Ras activation.
Constitutive localization of  C1-pbRasGRP3 enhanced
activation status of Ras before BCR stimulation, but the
Ras status was further activated upon BCR ligation, simply
suggesting that additional BCR-mediated event might be
required for optimal Ras activation. In this regard, consis-
tent with the previous data (68), we also detected the
BCR-mediated electrophoretic mobility shift of RasGRP3
in DT40 and primary B cells (unpublished data), presum-
ably reflecting phosphorylation status. Therefore, this phos-
phorylation-dependent modification could be a potential
additional mechanism.
Although initiation of Ras activation in BCR signaling
requires membrane localization of RasGRP3, the subse-
quent inactivation of Ras at 10 min after BCR stimulation
(Fig. 1 A) appears not to be simply explained by dissocia-
tion of RasGRP3 from the membrane. Indeed, our bio-
chemical and microscopic analyses indicated that RasGRP3
was still located in the membrane after 10 min of BCR
stimulation. Hence, inactivation of RasGRP3, indepen-
dently of membrane localization, might take place at this
time point, or RasGAPs might be activated, thereby lead-
ing to a decrease in active Ras.
Despite the common ability of RasGRP and Sos to acti-
vate Ras, the pathways to which these GEFs are coupled
seem not to be simply overlapping or redundant. Given
that various receptors such as c-kit and cytokine receptors
stimulate Ras and subsequent Erk, these pathways could
provide the B cells with the ability to discriminate between
these stimuli and possibly modulate the subsequent biologi-
cal responses.
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